Sofinnova Partners
Sofinnova leads £15m round for Green Biologics
Sofinnova Partners has led a £15.4m series-B funding round for Green Biologics, a UK-based chemicals producer, alongside Hong Kong-based Swire Pacific and several existing investors.
Sofinnova leads £2.4m round for CelluComp
Sofinnova Partners has led a £2.4m funding round for CelluComp, a Scottish sustainable materials company, with participation from the Scottish Investment Bank (SIB).
Sofinnova leads €15m round for Pixium
Sofinnova Partners has led a €15m extension of Pixium Vision’s two-part series-A round alongside BPI France and existing investors Omnes Capital and Abingworth Management.
Sofinnova Partners et al. sell EOS for up to €310m
Sofinnova Partners, Aescap Venture and Principia have sold Milan-based cancer therapeutics firm Ethical Oncology Science (EOS) to Clovis Oncology via an agreement that could see the firm fetch up to €310m.
Mission Therapeutics raises £20m
A syndicate of new and existing venture capital investors has injected £20m into UK-based biotech Mission Therapeutics as part of its series-B funding round.
Sofinnova, Forbion lead €20m round for Hookipa
A consortium of investors led by Sofinnova Partners and Forbion Capital Partners has invested €20m in a series-B funding round for Austria-based Hookipa Biotech.
Sofinnova et al. invest £1.3m in Synthace
Sofinnova Partners has led a £1.3m funding round for Synthace, a London-based applied synthetic bioengineering company, alongside a syndicate of angel investors.
Omega Funds leads $10m round for SpineVision
Omega Funds has led a $10m funding round for French medical devices provider SpineVision, which also included investments from two other new backers.
Sofinnova backs Auris Medical with CHF 47.1m
French VC Sofinnova Partners has joined US-based Sofinnova Ventures in a CHF 47.1m funding round for Auris Medical.
Sofinnova et al. invest in MetGen
Sofinnova Partners has led a €2.2m round for Finnish start-up MetGen, with participation from Finnish Industry Investment and Finnvera.
Sofinnova closes seventh fund on €240m
Sofinnova Partners has closed its seventh fund on the vehicle's €240m hard-cap.
Sofinnova closes largest European life sciences fund in years
Sofinnova Partners is due to announce a final close on its seventh life sciences fund in the second week of December, unquote” has learned. Kimberly Romaine reports
Sofinnova Partners lists DBV
Paris-based Sofinnova Partners has listed DBV Technologies, raising €40.5m in the IPO on NYSE Euronext Paris.
Sofinnova and Morningside back NuCana BioMed
Sofinnova Partners has led a series-A round for biopharmaceutical company NuCana BioMed alongside Morningside Ventures and other investors, with financing totaling £6.74m.
Sofinnova Partners backs Hookipa Biotech
Paris-based Sofinnova Partners has led a €7m series-A financing for biotechnology firm Hookipa Biotech.
Sofinnova leads £6m investment in Mission Therapeutics
Sofinnova Partners has led a £6m funding round for Cambridge-based drug development company Mission Therapeutics.